Mindray(SZ:300760) ZHESHANG SECURITIES·2025-11-04 13:04Investment Rating - The investment rating for the company is "Buy" [6] Core Insights - The company reported a revenue of 25.8 billion yuan for the first three quarters of 2025, a year-on-year decline of 12%, but Q3 revenue showed a positive growth of 1.5% year-on-year [1] - The net profit attributable to the parent company for the first three quarters was 7.6 billion yuan, down 29% year-on-year, with Q3 net profit at 2.5 billion yuan, a decline of 19% year-on-year [1] - The company’s overseas revenue in Q3 grew by 12% year-on-year, indicating an accelerating trend [1] Revenue Growth - The international business saw a 12% year-on-year growth in Q3, with Europe performing particularly well, exceeding 20% growth [2] - The minimally invasive surgery segment experienced over 25% growth, while the international life information and support line achieved double-digit growth [3] - The in-vitro diagnostics segment saw a 2.81% decline in Q3 revenue, but international sales in this segment grew by double digits [3] Profitability Analysis - The gross margin for the first three quarters of 2025 was 62.0%, a decrease of 2.9 percentage points year-on-year, while Q3 gross margin improved to 62.5%, up 0.79 percentage points year-on-year [4] - The net profit margin for 2025 was 30.2%, down 6.1 percentage points year-on-year, with Q3 net profit margin at 28.4%, down 6.5 percentage points year-on-year [4] Financial Forecast and Valuation - Revenue projections for 2025-2027 are 35.728 billion, 38.171 billion, and 42.879 billion yuan, with year-on-year growth rates of -2.72%, 6.84%, and 12.33% respectively [5] - The net profit attributable to the parent company is forecasted to be 10.563 billion, 11.760 billion, and 13.615 billion yuan for the same period, with corresponding year-on-year growth rates of -9.48%, 11.34%, and 15.77% [5] - The estimated EPS for 2025-2027 is 8.71, 9.70, and 11.23 yuan, with a PE ratio of 21 times for 2026 [5]